Baker Bros. Advisors LP Amends Kymera Therapeutics Stake

TL;DR

**Baker Bros. Advisors LP updated their Kymera Therapeutics stake, signaling a potential shift in their investment thesis.**

AI Summary

Baker Bros. Advisors LP, a Delaware-based investment firm, filed an amended SC 13G/A on January 10, 2024, disclosing their beneficial ownership of Kymera Therapeutics, Inc. common stock as of December 31, 2023. This filing indicates a change in their holdings, which is important for investors as Baker Bros. Advisors LP is a significant institutional investor in the biotechnology sector, and their movements can signal confidence or concern in Kymera's future prospects.

Why It Matters

This filing updates the public on a major institutional investor's position in Kymera Therapeutics, Inc., which can influence market perception and potentially the stock price.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of ownership by an institutional investor and does not inherently present a high risk.

Analyst Insight

Investors should monitor subsequent filings from Baker Bros. Advisors LP to understand the magnitude of any changes in their stake, as this could signal their long-term outlook on Kymera Therapeutics, Inc. and its drug pipeline.

Key Players & Entities

• Baker Bros. Advisors LP (company) — the reporting person and institutional investor
• Kymera Therapeutics, Inc. (company) — the subject company whose stock is being reported
• Felix J. Baker (person) — a group member associated with Baker Bros. Advisors
• Julian C. Baker (person) — a group member associated with Baker Bros. Advisors
• Delaware (company) — place of organization for Baker Bros. Advisors LP
• $0.0001 (dollar_amount) — par value per share of Kymera Therapeutics common stock

FAQ

Key Financial Figures

• $0.0001 — ame of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securiti

Filing Documents

• tm242265d1_sc13ga.htm (SC 13G/A) — 88KB
• 0001104659-24-002999.txt ( ) — 90KB

(a)

Item 1(a) Name of Issuer: Kymera Therapeutics, Inc. (the “Issuer”)

(b)

Item 1(b) Address of Issuer’s Principal Executive Offices: 200 Arsenal Yards Blvd., Ste. 230 Watertown, MA 02472

(a)

Item 2(a) Name of Person Filing: This Amendment No. 1 is being filed jointly by the Reporting Persons.

(b)

Item 2(b) Address of Principal Business Office or, if None, Residence: The business address of each of the Reporting Persons is: c/o Baker Bros. Advisors LP 860 Washington Street, 3 rd Floor New York, NY 10014 (212) 339-5690

(c)

Item 2(c) Citizenship: The Adviser is a limited partnership organized under the laws of the State of Delaware. The Adviser GP is a limited liability company organized under the laws of the State of Delaware. The citizenship of each of Julian C. Baker and Felix J. Baker is the United States of America.

(d)

Item 2(d) Title of Class of Securities: Common Stock, par value $0.0001 per share (“Common Stock”).

(e)

Item 2(e) CUSIP Number: 501575104 Item 3 If this statement is filed pursuant to §§240.13d-1(b) or (c), check whether the person filing is a: (a) ¨ Broker or dealer registered under Section 15 of the Exchange Act. (b) ¨ Bank as defined in section 3(a)(6) of the Exchange Act. (c) ¨ Insurance company as defined in section 3(a)(19) of the Exchange Act. (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940. (e) x An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E). (f) ¨ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F). (g) x A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G). (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act. (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940. (j) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(J). Item 4 Items 5 through 9 and 11 of each of the cover pages to this Amendment No. 1 are incorporated herein by reference. Set forth below is the aggregate number of shares of Common Stock directly held by each of Baker Brothers Life Sciences, L.P. (“Life Sciences”) and 667, L.P. (“667”, and together with Life Sciences, the “Funds”) which may be deemed to be indirectly beneficially owned by the Reporting Persons, as well as Common Stock that may be acquired upon exercise of pre-funded warrants with no expiration date with an exercise price of $0.0001 per share of Common Stock (“Pre-Funded Warrants”), subject to the limitations on exercise described below. The information set forth below is based on 55,487,373 shares of Common Stock outstanding as of October 27, 2023, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 2

View Full Filing

View this SC 13G/A filing on SEC EDGAR